INTRODUCTION
Ulcerative colitis is characterized by chronic inflammation and ulceration of the colonic mucosa. Several environmental and genetic factors are responsible for chronic inflammation. 1 Angiogenesis has been defined as growing of new blood vessels from the preexisting ones. In addition to playing a role in physiological events such as wound healing and growth, it is also seen in tumor development, metastasis, and chronic inflammation. 2 In inflammatory bowel disease (IBD), although angiogenesis is necessary for ulcer healing and tissue regeneration through providing oxygen and nutrients to the healing zone, it turns into a pathological process through inflow of inflammatory cells and cytokines. Under the influence of inflammatory mediators such as cytokines, growth factors and proteases that come to the healing site, angiogenesis increases further and the microvascular bed enlarges. In this manner, this condition becomes a vicious circle that attracts more inflammatory mediators to the center.
It thus leads to chronic inflammation. 3, 4 Previous studies have shown the existence of several angiogenic factors that may become elevated, such as vascular endothelial growth factor (VEGF), basic fibroblast growth factor (bFGF), platelet derived growth factor (PDGF), angiogenin and angiopoietin-2. [5] [6] [7] [8] VEGF is defined as the potent proangiogenic factor that is secreted by parenchymal, endothelial and activated immune cells. 9 Elevated serum and tissue levels of VEGF in patients with IBD have been shown in many studies. in the inflamed mucosa. 3, 4, 12 Endostatin is a 20-kDa fragment of collagen-18 that is generated by proteinases such as matrix metalloproteinases (MMPs), especially MMP-9. It acts as an endogenous angiogenesis inhibitor through inhibiting proliferation and inducing apoptosis of endothelial cells. 13 Endostatin downregulates many angiogenic factors, such as VEGF, bFGF, hepatocyte growth factor (HGF), hypoxia-induced-factor-1α (HIF-1α) and tumor necrosis factor-α (TNF-α)
and it upregulates anti-angiogenic genes such as thrombospondin-1, HIF-1α-inhibitor, etc.
14 Studies on the effects of endostatin in cases of ulcerative colitis have produced contradictory results. Sandor et al. reported the presence of increased levels of endostatin and angiostatin in the colonic mucosa, rather than increased levels of VEGF, in a study on experimental colitis. They speculated that the reason for the chronicity of the disease, decreased healing of mucosal lesions and lack of increased VEGF levels was the increased levels of endostatin and angiostatin. 15 In another study, they reported that the effect of 5-aminosalicylate acid (5-ASA) on the healing of ulcerative colitis (UC) may be related to downregulation of the anti-angiogenic factors endostatin and angiostatin. 16 In the present study, we aimed to evaluate the relationship between serum VEGF and endostatin levels and the clinical features of patients with ulcerative colitis, and to evaluate VEGF and endostatin expression in the colonic mucosa of these patients.
METHODS

Participants
The participants of this study were recruited according to their consecutive admittance to a gastroenterology outpatient clinic: yielding an ideal sample of 24 participants for the study group (21 for studying VEGF and 13 for studying endostatin) and 15
for the control group.
The UC clinical activity index (UCAI) was calculated as described by Seo et al. 18 The Rachmilewitz endoscopic activity index (EAI) was also calculated for the UC group. 19 Serum VEGF and endostatin levels were studied using ELISA (n = 82) Mucosal VEGF and endostatin expressions were studied using IHC (n = 57) Figure 1 . Flowchart of the study. UC = ulcerative colitis; IBS = irritable bowel syndrome; HCs = healthy controls; VEGF = vascular endothelial growth factor; ELISA = enzymelinked immunosorbent assay; IHC = immunohistochemistry. * The biopsy specimens from 6 patients with UC could not be evaluated because of insufficient material.
# Four patients did not undergo colonoscopic examination but also met the Rome III criteria for IBS.
132-3784) and was conducted in accordance with the revised Helsinki Declaration. Informed consent was obtained from all patients.
Serum VEGF and endostatin levels
Venous blood samples were taken after overnight fasting and were centrifuged at 10,000 rpm for 10 minutes. The resultant serum was collected and kept at -80 °C until the examination date. Serum VEGF levels and endostatin levels were measured in duplicate by means of enzyme-linked immunosorbent assays (ELISA) using commercial kits in accordance with the manufacturers' instructions (for VEGF: Biosource International, California, USA; and for endostatin: R&D Systems, Minneapolis, MN, USA).
Immunohistochemical analysis
Paraffin-embedded tissue material from the patients with UC 
Statistical analysis
The Statistical Package for the Social Sciences (SPSS) for Windows, version 15.0 (SPSS Inc, Chicago, IL, USA), was used for statistical analysis. The results were given as the mean ± standard deviation or as the median with minimum-maximum.
The normality of the distributions was checked.
To compare pairs of groups, the t test was used if the distribution was normal and the Mann-Whitney U test was used if the distribution was not normal. To make comparisons between more than two groups, analysis of variance (ANOVA) was used if the distribution was normal and the Kruskal-Wallis test was used if the distribution was not normal. The Mann-Whitney U test was used to compare pairs of subgroups. If the P value found in the test result was significant, multiple comparison tests were used to find out which group the difference originated from. P-values < 0.05 were considered statistically significant.
RESULTS
There were no significant differences among the three groups in terms of age and gender. The demographic characteristics of the study population and the drugs used by the patients with UC during the serum sampling are presented in Tables 1 and 2 .
There was also no significant difference in immunohistochemical expression among the patients, in terms of age and gender.
For UC patients (n = 33), the mean age was 45.4 ± 11.4 years and there were 13 females; while for IBS patients (n = 24), the mean age was 46.8 ± 12.1 years and there were 15 females.
A statistically significant difference between the groups was found in terms of serum VEGF and serum endostatin levels (P = 0.001 and P < 0.001, respectively) ( Table 1) . The difference was due to the UC group. There was no statistically significant difference between the patients with IBS and the healthy controls in terms of serum VEGF and endostatin levels (P = 0.709 and P = 0.562, respectively) (Figures 3 and 4) .
Comparison between the mean serum VEGF and serum endostatin levels according to the clinical activity of the UC patients showed statistically significant differences (P = 0.004 and P = 0.011, respectively) ( Table 3 ). There were significant differences between the groups with severe and moderate disease (P = 0.024) and between the groups with severe and mild disease (P = 0.04), but there was no significant difference between the groups with mild and moderate disease (P = 0.343), in terms of serum VEGF levels.
There were statistically significant differences between the groups with severe and mild disease (P = 0.015) and between the groups with moderate and mild disease (P = 0.030), but there was no difference between the groups with severe and moderate disease (P = 0.625), in terms of serum endostatin levels.
Comparison between the mean serum VEGF and endostatin values according to the disease involvement site in patients with UC did not show any significant differences (P = 0.826 and P = 0.867, respectively). The mean serum VEGF level in the proctitis group was 430.0 ± 340.0 pg/ml; in the group with left colon involvement, 529.12 ± 375.1 pg/ml; and in the pancolitis group, 530.5 ± 412.7 pg/ml. The mean serum endostatin level in the proctitis group was 157.6 ± 54.1 ng/ml; in the group with left colon involvement, 160.7 ± 66.5 ng/ml; and in the pancolitis group, 149.4 ± 58.3 ng/ml.
Grouping of the patients with UC according to endoscopic activity index, i.e. as active (n = 19) or inactive (n = 20), showed significant differences in terms of mean serum VEGF levels (660.2 ± 416.5 pg/ml and 371.0 ± 278.9 pg/ml respectively; P = 0.011) and mean serum endostatin levels (179.8 ± 65.1 ng/ml and 132.4 ± 44.6 ng/ml respectively; P = 0.012) There were statistically significant positive correlations between the serum VEGF and serum endostatin levels and the UCAI, ESR, CRP level and platelet count ( Table 4) .
There were statistically significant differences in the stroma, endothelium and epithelium between the active UC, inactive UC and IBS groups in terms of H-scores of VEGF expression (P < 0.001). This difference was based on the active group ( Table 5) .
Endostatin expression was not viewed in the epithelium in any group. There were statistically significant differences in terms of H-score for endostatin expression in the stroma between the active UC, inactive UC and IBS groups (P < 0.001); whereas there was only a statistically significant difference in terms of H-score for endostatin expression in the endothelium between the active UC and IBS groups (P = 0.043).
DISCUSSION
In the present study, we demonstrated for the first time that higher colonic mucosal expression of the potent angiogenic factor VEGF and the potent anti-angiogenic factor endostatin occurred, rather than elevated serum levels, in patients with UC. Comparison of serum VEGF and endostatin levels according to UCAI showed that the most notable difference was between the groups with severe and mild disease. In addition, there was a significant difference between the active and inactive groups, in terms of both serum VEGF and endostatin, through evaluation according to EAI. There was no difference between the groups through evaluation according to disease extent. There were positive correlations between UCAI and the VEGF, endostatin, ESR, CRP and platelet levels. Mucosal VEGF and endostatin expressions were higher in the active UC group than in the inactive UC group and IBS group.
There was no difference in mucosal VEGF and endostatin expressions between the inactive UC group and the IBS group.
The role of angiogenesis in IBD is double-sided. While it is necessary for wound healing and tissue repair, it also promotes UC = ulcerative colitis; IBS = irritable bowel syndrome; HC = healthy control; VEGF = vascular endothelial growth factor; IQR = interquartile range; ASA = aminosalicylic acid. *This was studied using one-way analysis of variance. The homogeneity of the variances was tested by means of the Levene test. The posthoc Tamhane test was used because the variances were not homogeneous. ** This was studied using the Kruskal-Wallis test. The Mann-Whitney U test was used in association with post-hoc analysis using the Bonferroni correction, and P < 0.017 was considered significant. *This was studied using one-way analysis of variance. The homogeneity of the variances was tested by means of the Levene test. The post-hoc Tukey test was used because the variances were homogeneous **This was studied using the Kruskal-Wallis test. The Mann-Whitney U test was used in association with posthoc analysis using the Bonferroni correction, and P < 0.017 was considered significant. that mesalazine treatment reduced the expression of endostatin and angiostatin through restoring the balance between MMM-2 and MMM-9 via TNF-α inhibition. 16 They did not demonstrate any effect of reducing the increase in VEGF expression.
Tolstonova et al. showed that there were concomitant increases in the levels of endostatin and VEGF. 21 They found a correlation between colonic lesion size and endostatin and VEGF levels.
Our study is compatible with their study in terms of the positive correlation between serum VEGF and endostatin levels. They stated that increased endostatin levels were a defensive response to the increased VEGF in UC. They also suggested that endostatin might be an alternative treatment for UC.
Konstatinos et al. found elevated levels of the proangiogenic molecules angiogenin and angiopoietin-2, along with higher serum levels of endostatin in UC patients with extensive colitis. 8 We did not find any correlation between serum VEGF and endostatin levels and the extent of the disease. Salem et al. reported that the levels of endostatin, angiostatin, VEGF and TNF-α were reduced through niacin treatment. 22 The complexity and range of pathways within the pathophysiology of chronic diseases have led to proposals for a number of options for treatments. The contribution of increased and unregulated angiogenesis in IBD, towards chronic inflammation, has long been known. It has been demonstrated that antiangiogenic therapy is effective against chronic inflammatory diseases such as arthritis, psoriasis and retinal neovascularization, and this suggests that it may also be effective for treating IBD.
The greatest limitations of our study were its cross-sectional nature and the small number of patients. Another limitation was that we were unable to evaluate mucosal expression in all of the patients whose serum levels of VEGF and endostatin we assessed.
There is a need for prospective studies to show whether the serum or tissue endostatin level increase or decrease through treatment.
Further experimental studies are also needed, to show the mucosal effect of local or systemic endostatin treatment.
CONCLUSIONS
The serum and tissue VEGF and endostatin levels were found to be higher in patients with UC, and especially in those with active disease. This finding may explain the chronicity of the disease and may also form the basis of an idea for a new treatment option for UC patients.
